Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/flightpath.bio/public_html/wp-content/themes/flightpath/template-parts/content-flexible.php on line 10

Flightpath's R&D team is building a comprehensive array of technologies to tackle the planet’s most biologically sophisticated pathogens.


Human Therapeutic Development Programs

Product Name Program Primary Pathogen Discovery Preclinical Clinical Marketed Development Partner
FP-100 acute Lyme borreliosis B. burgdorferi internal

Description:

FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

FP-101 persistent Lyme disease B. burgdorferi internal

Description:

FP-101 is a previously FDA-approved IV antibiotic that has been transitioned into a targeted-delivery oral therapeutic for the treatment of persistent Lyme infections while reducing impact on the gut microbiome.

 

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

FP-100 syphilis, yaws, periodontal disease, leptospirosis T. pallidum,
T. denticola, Leptospira
internal

Description:

FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

Microbiome Discovery Program

Product Name Program Primary Pathogen Discovery Preclinical Clinical Marketed Development Partner
Microbiome Signature Chronic Lyme disease diagnostic TBD - proprietary external - partnered

Description:

Both the underlying mechanism responsible for chronic Lyme disease symptoms, as well as a reliable diagnostic tool, has remained elusive.

Analysis of data from a rigorously curated cohort of chronic Lyme disease patients revealed a gut microbiome signature distinct from that of healthy control subjects, as well as from that of intensive care unit (ICU) patients,  which presents a potential, novel diagnostic tool for chronic Lyme disease.

Ownership:

Global development and commercialization rights have been partnered with a scaled diagnostic manufacturing partner.

Microbiome Consortia Chronic Lyme therapeutic TBD - proprietary internal

Description:

A therapeutic bacterial probiotic consortia program to repair dysbiosis in the microbiomes of chronic Lyme disease patients

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

Flightpath is seeking partners interested in developing agricultural and animal health applications.

Contact Us for more information